A Phenotypic High Throughput Screening Assay for the Identification of Pharmacoperones for the Gonadotropin Releasing Hormone Receptor

P. Michael Conn, Emery Smith, Timothy Spicer, Peter Chase, Louis Scampavia, and Jo Ann Janovick

1Departments of Internal Medicine and Cell Biology/Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas.
2Lead Identification Division, Translational Research Institute, Scripps Research Institute, Jupiter, Florida.

ABSTRACT
We describe a phenotypic high throughput screening (HTS) calcium flux assay designed to identify pharmacoperones for the gonadotropin releasing hormone receptor (GnRHR). Pharmacoperones are target-specific, small molecules that diffuse into cells, rescue misfolded protein mutants, and restore them to function. Rescue is based on correcting the trafficking of mutants that would otherwise be retained in the endoplasmic reticulum and unable to function correctly. This approach identifies drugs with a significant degree of novelty, relying on cellular mechanisms that are not currently exploited. Development of such assays is important, since the extensive use of agonist/antagonist screens alone means that useful chemical structures may be present in existing libraries but have not been previously identified using existing methods. Our assay utilizes cell lines stably expressing a GnRHR mutant under the control of a tetracycline (OFF) transactivator. This allows us to quantitate the level of functional and properly trafficked G protein coupled receptors present in each test well. Furthermore, since we are able to turn receptor expression on and off, we can rapidly eliminate the majority of false positives from our screening results. Our data show that this approach is likely to be successful in identifying hits from large chemical libraries.

INTRODUCTION

GPCRs, which include the gonadotropin releasing hormone (GnRH) receptor (GnRHR), comprise the largest family of validated drug targets—35%–50% of approved drugs derive their benefits by selective targeting of GPCRs. High throughput screen (HTS) assays for drugs targeting GPCRs have been identified using screens for either agonists or antagonists. Our work and that of others shows that valuable drugs that affect the trafficking of GPCRs may have been overlooked because of this limitation. Mutations in GPCRs frequently result in misrouted proteins and are known to be responsible for more than 30 disorders, including cancers, heritable obesity, and endocrine disease. Included in this group is hypogonadotropic hypogonadism (HH) caused by mutations in the GnRHR, and other disorders of reproduction that result from inappropriately decreased plasma membrane expression of the WT receptor. The GnRHR resides in the gonadotrope cells of the pituitary and is responsible for producing responses to hypothalamic GnRH, such as the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). The human GnRHR (hGnRHR) has been a central focus of drug development, and understanding the mechanism of GnRH action has already led to useful drugs (agonists and antagonists). Normally, GPCRs are subjected to a stringent quality control system (QCS) in the endoplasmic reticulum (ER). This system consists of both protein chaperones that retain misfolded proteins and enzyme-like proteins that catalyze the folding process. The QCS, consisting of endogenous chaperones, which assesses structure but not function, ensures that only correctly folded proteins enter the pathway leading to the plasma membrane (PM). Because of this, point mutations may result in the production of misfolded and disease-causing proteins that are unable to reach their functional destinations in the cell because they are retained by the QCS even though they may retain (or regain) function.

The functional rescue of misfolded mutant receptors by small nonpeptide molecules (pharmacoperones), originally screened from libraries to serve as receptor antagonists, has now been demonstrated. A pharmacop erone is a small molecule that enters cells and serves as a “molecular scaffold” to promote correct folding of otherwise misfolded mutant proteins within the cell. Misfolded proteins are frequently retained by the cellular QCS of the ER, do not reach their normal site of function, and may result in disease. Pharmacoperones rescue misfolded receptor mutants and restore them to function, which is a potentially useful therapeutic approach when the target is a misfolded/misrouted protein.

We summarized the literature for the pharmacoperones of the GnRH with a view toward moving these compounds in vivo. Science writers commenting on this work have observed that rescue with pharmacoperones is a viable “alternative (to gene therapy),” since it serves as a means of “skirting gene therapy to correct genetic defects.” This view is supported by the consideration that correction of defective protein folding appears significantly less challenging than replacement of a defective gene (or gene product) by a perfect one. Protein rescue with pharmacoperones results from proper folding, passage through the QCS, restoration to the proper site, and return of function.
All pharmacoperone drugs identified to date for the GnRHR were identified from hits in HTS screens for receptor antagonists and repurposed. These must be removed after rescue to preclude competition with agonists. This results in a complex pharmacology for drug administration. This therapeutic problem will be addressed by identification of drug candidates in the proposed assays that are pharmacoperones but lack antagonistic activity.

Recently, we have developed a mouse phenotype expressing the E90K mutation of the GnRHR that causes HH in humans and mice. Conditions for pharmacoperone-rescue of this mutant in vivo have been established,24 and this animal establishes in vivo proof of concept for the efficacy of this class of drugs.

**MATERIALS AND METHODS**

**Materials**

- IN3, (((2S)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-pyridin-4-yloxyethyl)-N-pyrimidin-4-yl-3-(3,4,5-trimethylphenyl)-1,2-dihydroquinoline-6-carboxamide), both positive control compounds, were a kind gift from Merck and Company and were discovered as peptidomimetic antagonists of the GnRHR receptor. The pilot library (LoPAC) was obtained from Sigma-Aldrich (St. Louis, MO) and stored as 2.5 mM dimethylsulfoxide (DMSO) stock solutions at −20°C in sealed polypropylene plates. The stable cells were created in HeLa cells as previously described.25 The GnRHR agonist was synthesized and biologically characterized by us. Fetal bovine serum (FBS) was obtained from HyClone (Logan, UT).

**HTS Optimized Primary GnRHR Pharmacoperone Assay**

HeLa cells stably expressing GnRHR[E90K] under the control of a tetracycline-controlled transactivator were cultured in growth medium (1x Dulbecco’s modified Eagle’s medium [DMEM] + 10% FBS and 1 mg/L gentamicin) as described in Table 1. On the day of screening, cells were trypsinized and added to plates (20 μL/well, 8,500 cells/well). This was followed immediately by pin-tool addition (Kalypsys, San Diego, CA) of test compounds and controls (positive control was 100 nM IN3 or Q89 as specific; negative control was carrier only) in 100 nL DMSO. The drugged plates were incubated for 17 h at 37°C, 5% CO2 prior to addition of 20 μL of Fluo-2 dye. Following a 1 h incubation at 37°C, 5% CO2, and 30 min room temperature equilibration with dye, 5 μL of GnRH (500 nM final) was added in assay buffer (HBSS+ 20 mM HEPES+ 3% DMSO) followed by determination of calcium release by the FLIPR. We use a sensitive, nonradioactive, homogenous “mix-and-read” HTS assay protocol, which measures Ca2+ levels via a Fluo-2 a calcium sensitive cell permeable dye (Fig. 1). The optimized counterscreen was identical to the primary screen described except that cells were cultured in the presence of 1 μg/mL doxycycline for 36 h prior to plating and during all phases of the experiment.

**Data Processing**

The raw fluorescence data were interpreted as a ratio of Max/Min values, which were normalized to positive and negative controls to give percent response scores. Dose–response curves were fit using a four-parameter variable slope sigmoidal curve in GraphPad Prism 5.02 (GraphPad Software, La Jolla, CA). Concentration response curves were generated using Graphpad software via a four-parameter equation, which yield sigmoidal concentration response curves fitted using nonconstrained upper and lower boundaries parameters and variable slope.

**RESULTS**

**Overview of the Assay**

In this HTS, the level of functional GnRHR present in each test well is quantitated using a calcium sensitive dye FLIPR-based assay system (Fig. 1). This technique allows the screen to identify compounds that increase the trafficking of mutant GnRHR[E90K] in our model system. To triage assay artifact and compounds with intrinsic off-target activity, compounds are counterscreened with the same cell
line as the primary assay, except in the presence of doxycycline, which shuts off the GnRHR[E90K] expression.

**The GnRHR Mutant**

We selected mutant GnRHR[E90K] as the basis of our screen; this mutant causes human HH. Modeling studies for the hGnRHR and experimental data support the view that the E90-K121 salt bridge is a fundamental and evolutionarily conserved determinant required for correct protein trafficking to the PM in all mammals examined. Modeling studies for the hGnRHR and experimental data support the view that the E90-K121 salt bridge is a fundamental and evolutionarily conserved determinant required for correct protein trafficking to the PM in all mammals examined.27–29 This bridge links transmembrane segment 2 (TMS2) to TMS3. Because this salt bridge is a requirement for correct routing, mutation E90K results in a routing defect in both mouse and human GnRHR.30,31 This leads to full but pharmacoperone rescuable ER-retention and the predicted phenotype in humans12 and mice.33

**Pharmacoperone IN3 rescues mutants of the GnRHR.** When cells expressing mutant GnRHR[E90K], which is recognized by the cellular quality control system as defective and retained in the ER, are incubated with IN3, the mutant is rescued.8,33–35 This pharmacoperone rescues many mutants of the hGnRHR, is GPCR-specific, and was used as a positive control in our assay development.34,36

**The GnRHR pharmacoperone primary HTS and counterscreen.** GnRHR[E90K] activity is coupled to Ca2+ flux. The primary assay for this project uses a HeLa cells constitutively expressing GnRHR[E90K] controlled by a tetracycline-regulated trans-activator.25,37 In the absence of doxycycline (a stable analog of tetracycline), the mutant is expressed; it is then misrouted and retained in the endoplasmic reticulum (ER).

Following pretreatment with pharmacoperone, the mutant is rescued and trafficked to the plasma membrane. The rescued mutant

---

**Fig. 1.** Gonadotropin releasing hormone (GnRH) receptor (GnRHR) pharmacoperone assay principle. The mutant GnRHR is retained in the lumen of untreated cells. Addition of pharmacoperone rescues GnRHR, and the receptors are trafficked to the plasma membrane. GnRHR on the plasma membrane is now responsive to agonism by GnRH, which is quantitated using Fluo-2 detection reagents (box). The level of functional GnRHR (mutant) is proportional to the magnitude of Gq modulated signaling, IP3 induction, and subsequent Ca2+ released and detected in the cells via Fluo2 using the FLIPR Tetra reader as illustrated via the kinetic traces shown in the lower inset diagram.
is then responsive to native GnRH and signals, via Gq coupling, resulting in the subsequent PLC-β activation leading to PIP2 hydrolysis into IP3. IP3 in turns affects the release of intracellular Ca^{2+}, which is readily quantified via Fluo-2 dye using the FLIPR Tetra reader.

The counterscreen protocol is identical to the primary HTS assay protocol with the exception that the GnRHR[E90K] cells are incubated in the presence of 1 µg/mL of doxycycline ("Dox") for 36 h prior to assay. During this time, the gene for the mutant is off, and no measurable mutant remains in the cell. Accordingly, the GnRHR[E90K] primary assay and counterscreen protocols confirm the expected pharmacology of positive and negative controls (Fig. 2). As a point of comparison, IN3 was originally designed as a GnRHR antagonist. The result with IN3 validates using the Dox + GnRHR[E90K] Fluo-2 assay as the counterscreen for identification and elimination of pharmacoperone hits that are also antagonists.

The IN3 pharmacoperone yields an EC50 of 5.12 ± 1.60 nM in the "-Dox" assay, and a signal-to-background ratio (S/B) of ~2.5 (n=4). Both protocols are high throughput compatible in both 384- and 1,536-well formats, although the data presented here are obtained using a 384-well format.

An additional control compound of a different chemical class, Q89, was also tested and generated an EC50 of 1.9 nM (Fig. 3).

LOPAC pilot screen

The Sigma LOPAC (Library of Pharmacologically Active 1280 Compounds) was screened to determine the performance of the optimized GnRHR[E90K] pharmacoperone assay in terms of robustness (Z’). Briefly, compounds were analyzed at a single concentration of nominally 6 µM (0.2% DMSO) using IN3 as a positive control. Each plate contained high and low signal control wells, which were used in Z’ factor calculations. An activity scatterplot of all compounds tested, as well as positive and negative controls, is shown in Figure 4A. As indicated from the positive and negative...
control scatterplots, the assay demonstrated an acceptable Z’ factor (0.57 ± 0.06; n = 12 plates) for the entire LOPAC screen, indicative of an assay that is amenable to HTS.

Day-to-day reproducibility of the assay is also excellent as indicated by the control pharmacoperone IN3, which, met with the expected sensitivity during this LOPAC pilot HTS, is referenced in Figure 4B. Achieving passing Z values along with the expected pharmacology of the control allows us to proceed to hit analysis. In spite of having a low average activity for the tested compounds (results in triplicate) and using a nominal hit-cutoff (85) of 18.24% (average ± 3 SD of sample field), no hits were identified. This is not unexpected based on the limited number of compounds in the LOPAC collection and the complexity of the target. LOPAC is a small library containing no structures that are similar to any of the controls based on a Tanimoto score > 90. Based on results from previous cell-based screens, we anticipate an actual HTS hit rate < 1%.

Although the LOPAC screen yielded low activities, 10 compounds with the highest activities were reexamined and a subset with notable Dox−/Dox+ differentiation from their respective screens was found and is presented in Table 2.

**Confirmation of Mechanism of Action and Specificity**

Compounds that show doxycycline-dependent signals will be profiled for specificity and potential mechanism of action using several plate-based high throughput assays. First, all hits will be tested for nonspecific cytotoxicity in unmodified human cell lines (BJ, HEPG2, and HEK293). Second, to determine if the observed pharmacoperone effect is specific to GnRHR or to a broader misrouted protein rescue phenomena, compounds showing activity in the GnRHR[E90K] Fluo-2 assay will be tested in our GnRHR[E90K] IP-One assay. This assay is identical to that for Fluo-2 assay, but measures the functional rescue of the ER-retained mutant E90K by quantitating levels of inositol phosphate one (IP1—a downstream marker for GnRHR activation). This assay has been optimized in 384-well format and published by our groups.

In addition to these high throughput assays, a range of lower throughput approaches are available to characterize primary hits fully. The first of these is a well-characterized orthogonal endpoint, IP production, which has been in use in our group for more than 25 years and which shows good agreement with the high throughput assay system described above. This (IP) assay will identify artifacts arising from the Fluo-2 used in the primary HTS effort. Second, the ability of compounds to increase the amount of hGnRHR at the cell surface will be assessed using the well-established 125I-Buserelin (metabolically stable GnRH agonist) binding assay as well as by monitoring cellular localization of GFP-tagged GnRHR[E90K] in transiently transfected...
COS-7 cells. GFP-tagged-GPCR approaches are well established and have been used in Conn’s group and elsewhere for studying the localization of GnRHR. The combination of these approaches will allow us to confirm that primary hits are increasing levels of the downstream hGnRHR activation marker (IP production) by increasing the total amount of correctly folded receptor at the cell surface (increased $^{125}$I-Buserelin and decreased GFP-hGnRHR in the ER). Compounds able to do so will be classified as validated hits.

**DISCUSSION**

For more than 20 years, there has been interest in the use of gene therapy to correct mutational disease. Issues related to the integration of therapeutic DNA into the genome, immune responses, technical problems with vectors (toxicity, immune, inflammatory responses, gene control, and targeting issues), chances of inducing tumors, (insertional mutagenesis), and other problems have made it challenging to reduce this approach to routine practice. Correcting the folding of misfolded protein mutants and restoring them to function (with pharmacoperon drugs) is a potential alternative to replacing them by gene therapy.

It is likely that valuable drugs reside in chemical libraries yet have been missed, since screening approaches that rely on identification of agonists and antagonists would have failed to identify pharmacoperone drugs. There are several advantages to using pharmacoperones, including the ability to restore misfolded proteins to function and not leave residual proteins behind that can result in activation of the unfolded protein response (UPR), an event that causes other metabolic problems. One example of such problems is, if left unchecked, the UPR leads to cell death, an event believed to have evolved to remove unregulated cells from organisms. Another example includes the observations that in patients with retinitis pigmentosa, retinal cells undergo apoptosis due to retention of the causative mutant of rhodopsin, a GPCR. Further, in type 2 diabetes, β cells become damaged by elevated demand for insulin and UPR activation. Pharmacoperone drugs may provide a new way to accomplish this goal.

Pharmacoperone rescue potentially applies to a diverse array of human diseases that result from misfolding (these include cystic fibrosis, nephrogenic diabetes insipidus, retinitis pigmentosa, hypercholesterolemia, cataracts, neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s, cancer, α1 trypsin deficiency and lysosomal storage disease, mucopolysaccharidosis type IIIC, and many others). One could envision drugs given in a prophylactic manner (e.g., in vitamins) that prevent the misfolding that leads to neurodegenerative disorders (Alzheimer’s—misfolded amyloid) Parkinson’s (misfolded α-synuclein), and cataracts (misfolded lens crystalline). In this regard, diseases may be prevented before clinical signs present. In the case of certain proteins (e.g., the GnRHR, V2R, and rhodopsin), this approach has succeeded with a striking number of different mutants supporting the view that pharmacoperones will become powerful weapons in our therapeutic arsenal. Most pharmacoperones identified to date and all pharmacoperones of the GnRHR have been identified from screens that were developed to select antagonists. Accordingly, these drugs have both pharmacoperone and antagonist activity, which is
therapeutically undesirable and presents a complex pharmacology. It has not been established whether binding at or near the binding site of the natural ligand is necessary for pharmacoperone activity, and there is existing information to suggest otherwise. This would, in fact, be an unexpected requirement, since one could imagine pharmacoperones that might stabilize the correctly routed form of the receptor and not show any antagonism (or agonism). Accordingly, identification of nonantagonistic pharmacoperones is a reasonable and therapeutically important goal. Further, this will provide insight into the mechanism of pharmacoperone action. These screens will identify therapeutic agents for human and animal disease and provide a much-needed framework and proof of principle for identification of pharmacoperone drugs for other GPCRs.

The physiology of GnRHR is well characterized in many animal models. A great deal of information is also available regarding the cellular mechanism of action and trafficking of the GnRHR. We have available substantive information on the mechanism of misfolding, mutant interactions with pharmacoperones, and the molecular basis of the dominant-negative effect. Two additional observations are important, since these extend the therapeutic potential of these drugs. First, pharmacoperone drugs need not be present at the time of protein synthesis, but can rescue ER-retained proteins that have already accumulated. Observation increases the therapeutic reach, since misfolded mutants need not be (first) degraded and then replaced by newly synthesized protein (i.e., the portion synthesized in the presence of pharmacoperone).

Second, while pharmacoperones are specific for individual proteins, those that rescue one mutant of an individual protein typically rescue most mutants of the same protein, likely by stabilizing a core region that makes the protein acceptable to the quality control system of the cell. This observation improves the therapeutic reach of these drugs, since each mutant of an individual protein will not require a separate drug.

We anticipate that data from identification of GnRHR pharmacoperones will provide a range of benefits. First, validated hits discovered will serve as the basis for developing potential therapeutic use in the treatment of HH.

Further, while GnRHRs is typically only expressed in the pituitary gonadotrope, it is also paradoxically expressed in virtually all melanomas, about 80% of human endometrial and ovarian cancers, and about 50% of breast cancers including triple-negative breast cancer, as well as bladder, colorectal, and pancreatic cancers, sarcomas, lymphomas, prostatic cancers, and renal cell carcinomas. For these cells, GnRH agonists are negative regulators of cancer growth. For example, activation of the GnRHR by exogenous agonists inhibits the proliferation of melanoma growth both in vitro and in vivo, indicating a direct antitumor activity of this class of compounds. Additionally, toxins conjugated to GnRHR agonists are effectively targeted to melanoma cells where they show anti-angiogenic, anti-metastatic, and anti-oncogenic behavior. When GnRHR agonists or GnRH-toxin conjugates are used to treat melanoma, it is desirable to use the lowest dose consonant with therapeutic response, so as to limit side effects (i.e., androgen deprivation due to pituitary desensitization or nonspecific actions of the toxins). Pharmacoperones increase trafficking of the WT human GnRHR to the plasma membrane, a process that is otherwise about 50% efficient (i.e., about 50% is retained in the ER). Since selectively increasing the number of melanoma GnRHRs also increases the sensitivity of these cells to GnRH agonist, we expect that pharmacoperones will increase the sensitivity of these cells to GnRH agonist treatment, as well as to the toxin-GnRH conjugates. An additional use involves a subset of infertile women with responses to GnRH, suggesting a low plasma membrane expression of GnRHR. This is a candidate target for increased expression of WT GnRHR by pharmacoperones.

Control of anterograde (endoplasmic reticulum to plasma membrane) GnRHR trafficking is likely a key step in setting plasma membrane levels of this receptor, since it lacks binding sites for arrestin. Arrestin is associated with rapid retrograde trafficking (internalization).

In addition, compounds that more broadly affect protein folding and trafficking may be identified in this effort. The novel assay screening approach used in this project will provide a basis for other researchers interested in identifying small molecules that regulate protein trafficking.


Address correspondence to:
P. Michael Conn, PhD
Texas Tech University Health Sciences Center
3601 4th St.
Lubbock, TX 79430
E-mail: michael.conn@ttuhsc.edu

Abbreviations Used

ER = endoplasmic reticulum
FBS = fetal bovine serum
FSH = follicle stimulating hormone
GnRH = gonadotropin releasing hormone (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)
GnRHR = gonadotropin releasing hormone receptor
GPCRs = G protein coupled receptors
HH = hypogonadotropic hypogonadism
HTS = high throughput screen
IN3 = [2S]-2-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3-dimethylphényl)-1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine
LH = luteinizing hormone
Q89 = [7-chloro-2-oxo-4-[2-(2S)-piperidin-2-ylethoxy]designed-N- pyrindin-4-yl]-3-(3,4,5-trimethylphenyl)-1,2-dihydroquinoline- 6-carboxamide
QCS = quality control system
UPR = unfolded protein response